Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00BPE
|
||||
| Former ID |
DIB003573
|
||||
| Drug Name |
AVE-1642
|
||||
| Synonyms |
EM-164; Anti-IGF-1 receptor antibody (cancer), Aventis; Anti-IGF-1 receptor antibody (cancer), ImmunoGen; Anti-insulin-like growth factor-1 receptor antibody, Aventis; Anti-insulin-like growth factor-1 receptor antibody, ImmunoGen; Anti-IGF-1 receptor antibody (cancer), sanofi-aventis; Anti-insulin-like growthfactor-1 receptor antibody, sanofi-aventis
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Breast cancer [ICD9: 174, 175; ICD10:C50] | Discontinued in Phase 2 | [1] | ||
| Company |
ImmunoGen Inc
|
||||
| Target and Pathway | |||||
| Target(s) | Insulin-like growth factor I receptor | Target Info | [2] | ||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| FoxO signaling pathway | |||||
| Oocyte meiosis | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| AMPK signaling pathway | |||||
| Focal adhesion | |||||
| Adherens junction | |||||
| Signaling pathways regulating pluripotency of stem cells | |||||
| Long-term depression | |||||
| Ovarian steroidogenesis | |||||
| Progesterone-mediated oocyte maturation | |||||
| Pathways in cancer | |||||
| Transcriptional misregulation in cancer | |||||
| Proteoglycans in cancer | |||||
| Glioma | |||||
| Prostate cancer | |||||
| Melanoma | |||||
| PANTHER Pathway | Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade | ||||
| Insulin/IGF pathway-protein kinase B signaling cascade | |||||
| Pathway Interaction Database | Plasma membrane estrogen receptor signaling | ||||
| SHP2 signaling | |||||
| IGF1 pathway | |||||
| Posttranslational regulation of adherens junction stability and dissassembly | |||||
| Integrins in angiogenesis | |||||
| Stabilization and expansion of the E-cadherin adherens junction | |||||
| Reactome | IRS-related events triggered by IGF1R | ||||
| SHC-related events triggered by IGF1R | |||||
| WikiPathways | Senescence and Autophagy in Cancer | ||||
| Insulin Signaling | |||||
| Endochondral Ossification | |||||
| Focal Adhesion | |||||
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | |||||
| Apoptosis | |||||
| Signaling Pathways in Glioblastoma | |||||
| TSH signaling pathway | |||||
| MicroRNAs in cardiomyocyte hypertrophy | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021953) | ||||
| REF 2 | Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growthfactor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5445-56. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.